Abstract
The authors studied the pharmacokinetics of levodopa (LD) with and without pramipexole (PPX) in men and postmenopausal women with PD. Patients on stable dose of carbidopa/LD were randomized to receive escalating doses of placebo or PPX over 7 weeks. LD and PPX pharmacokinetics were performed after a single test dose 25/100 of carbidopa/LD, before initiation of PPX or placebo, at 1.5 mg/d and 4.5 mg/d of PPX or placebo. Compared to men, women had greater LD bioavailability. PPX did not alter LD bioavailability, and PPX pharmacokinetics were equivalent in men and women.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antiparkinson Agents / pharmacokinetics*
-
Area Under Curve
-
Benzothiazoles
-
Biological Availability
-
Carbidopa / pharmacology
-
Dose-Response Relationship, Drug
-
Drug Interactions
-
Enzyme Inhibitors / pharmacology
-
Female
-
Humans
-
Levodopa / pharmacokinetics*
-
Male
-
Parkinson Disease / drug therapy*
-
Postmenopause
-
Pramipexole
-
Sex Factors
-
Thiazoles / pharmacokinetics*
Substances
-
Antiparkinson Agents
-
Benzothiazoles
-
Enzyme Inhibitors
-
Thiazoles
-
Levodopa
-
Pramipexole
-
Carbidopa